Ftse Mib
34.335,29
0,44%
DAX
20.024,66
0,58%
S&P 500
5.868,55
-0,22%
NASDAQ
19.280,79
-0,16%
Bitcoin
96.799,52
2,55%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Monte Rosa Therapeutics Inc (GLUE) Monte Rosa Therapeutics Inc (GLUE) Notizie

GLUE

Monte Rosa Therapeutics (GLUE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GLUE
DataOraFonteTitoloSimboloCompagnia
13/12/202415:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
13/12/202415:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
13/12/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
13/12/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of DirectorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
11/12/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue DegradersNASDAQ:GLUEMonte Rosa Therapeutics Inc
11/12/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast CancerNASDAQ:GLUEMonte Rosa Therapeutics Inc
05/12/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid TumorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/11/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
13/11/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
07/11/202413:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
07/11/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
28/10/202412:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue DegradersNASDAQ:GLUEMonte Rosa Therapeutics Inc
23/10/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid TumorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
28/08/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
19/08/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudyNASDAQ:GLUEMonte Rosa Therapeutics Inc
08/08/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
08/07/202414:36GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation DayNASDAQ:GLUEMonte Rosa Therapeutics Inc
27/06/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160NASDAQ:GLUEMonte Rosa Therapeutics Inc
14/06/202414:45GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid ArthritisNASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Leadership Team PromotionsNASDAQ:GLUEMonte Rosa Therapeutics Inc
21/05/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseNASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202422:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/05/202422:01GlobeNewswire Inc.Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:GLUEMonte Rosa Therapeutics Inc
09/05/202413:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
02/05/202422:01GlobeNewswire Inc.Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerNASDAQ:GLUEMonte Rosa Therapeutics Inc
14/03/202412:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
11/03/202412:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorNASDAQ:GLUEMonte Rosa Therapeutics Inc
08/01/202413:15GlobeNewswire Inc.Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024NASDAQ:GLUEMonte Rosa Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GLUE

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
IVG
Iveco Group NV
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
MONC
Moncler
BIT
SRG
Snam
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network